Relay Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 323
- Market Cap
- $955.9M
- Website
- http://www.relaytx.com
- Introduction
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Conditions
- PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive TumorBreast CancerMetastatic Breast CancerAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT06982521
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
- Conditions
- PIK3CA-Related Overgrowth Spectrum (PROS)Lymphatic MalformationsVascular MalformationsPIK3CA MutationCLOVES SyndromeKlippel Trenaunay SyndromeMegalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT06789913
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Conditions
- HER2-negative Breast CancerBreast CancerUnresectable Solid TumorPIK3CA MutationSolid Tumor, AdultHormone Receptor Positive TumorMetastatic Breast CancerAdvanced Breast Cancer
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT05759949
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Community Cancer Center North, Indianapolis, Indiana, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
- Conditions
- PIK3CA MutationSolid Tumor, AdultHER2-negative Breast CancerBreast CancerMetastatic Breast CancerAdvanced Breast CancerUnresectable Solid TumorEndometrial Cancer
- Interventions
- Drug: PF-07220060 100mgDrug: PF-07220060 300 mg
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 890
- Registration Number
- NCT05216432
- Locations
- 🇺🇸
HealthONE, Denver, Colorado, United States
🇪🇸START Barcelona, Barcelona, Catalonia, Spain
🇪🇸Institut Catala D'Oncologia - Badalona (ICO Badalona), Barcelona, Spain
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
- Conditions
- FGFR2 Gene TranslocationFGFR2 Gene ActivationCholangiocarcinomaOther Solid Tumors, AdultFGFR2 Gene MutationFGFR2 AmplificationFGFR2 Gene Fusion/RearrangementIntrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Elevar Therapeutics
- Target Recruit Count
- 540
- Registration Number
- NCT04526106
- Locations
- 🇩🇪
LMU Klinikum, Campus Grosshadern, Munich, Germany
🇳🇱Netherlands Cancer institute, Amsterdam, Netherlands
🇳🇱Erasmus MC, Rotterdam, Netherlands